Project Grant R01CA294646
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$607K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This $218,068 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research conducted by the Scripps Research Institute to elucidate the molecular mechanism of microhomology-mediated end joining (MMEJ) by DNA polymerase theta (Pol θ). The research aims to gain insights into this error-prone DNA repair process, which is often utilized by BRCA1/2-deficient cancers. Key activities include using biochemical and structural biology...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research in New York. The grant will fund research to determine the role of key proteins like RAD52, HELQ, and POLQ in backup DNA double-strand break repair pathways in homologous recombination deficient (HRD) cancers. The project aims to discover additional proteins involved in these alternative repair mechanisms...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program will support research to investigate the role of mutagenic DNA repair in the persistence of cancer cells and the development of acquired drug resistance. The $238,722 award to the Sloan-Kettering Institute for Cancer Research in New York will fund work to (1) study persistence in response to PARP inhibitor treatment of BRCA1/2-mutant cancer cells, (2) examine mechanisms of mutagenic DNA...
The National Cancer Institute (NCI) awarded a $1,063,710 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Johns Hopkins University. The 5-year grant, effective August 1, 2024, will support research on the epigenetic mechanisms controlling single-stranded DNA lesion sensitivity and mutagenesis. The project aims to investigate the role of alternatively spliced histone variant MacroH2A1 isoforms in single-stranded DNA lesion repair, their impact on genome...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) will fund a 5-year research project led by an independent researcher at The Institute For Cancer Research in Philadelphia, PA. The total award amount is $470,000, with a project period from September 17, 2024 to August 31, 2029. The goal of this project is to characterize the molecular-level interactions and coordination events that...
The National Cancer Institute (NCI) awarded a $581,381.00 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research. The grant, with a period of performance from June 2025 to May 2030, will support research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. Specifically, the research aims to better understand DNA damage repair pathways and how they can...
This $1,104,864 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research at the University of California, Davis to understand the molecular mechanisms of homologous recombination (HR) and how defects in recombinational DNA repair can lead to chromosomal instability and cancer predisposition. The key objectives are to elucidate the functions of BRCA2 protein and the RAD51 paralogs in mediating and potentiating homologous DNA pairing by...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $445,000.00 in funding to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on the molecular mechanisms of DNA double-strand break repair by homologous recombination. The primary goal of this 5-year project is to elucidate the fundamental mechanisms of homologous recombination, a high-fidelity DNA repair pathway whose...
The National Institute of General Medical Sciences (NIGMS) awarded a $1,350,554 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to the Sloan-Kettering Institute for Cancer Research in New York, NY. This 5-year grant, effective August 10, 2024 through July 31, 2029, will support research to illuminate the molecular mechanisms of eukaryotic chromosome replication and investigate how DNA replication stress impacts genome stability and disease. The project aims to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate the mechanisms underlying resistance to PARP inhibitor (PARPi) drugs in prostate cancer and identify strategies to overcome this resistance. The Mayo Clinic, a renowned non-profit academic medical center, is the prime recipient of this $633,705 grant awarded on December 11, 2024, with a planned completion date of November 30, 2029. The key objectives of this research...